ArticleReproductive biology and endocrinology : RB&E2025
Association of serum anti-Müllerian hormone levels with early miscarriage: a retrospective cohort and mendelian randomization study.
Article in Reproductive biology and endocrinology : RB&E, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundWhile anti-Müllerian hormone (AMH) serves as a well-established biomarker of ovarian reserve, its association with early miscarriage risk remains inconsistently characterized across previous research. To address this evidence gap, our investigation systematically evaluates the relationship between serum AMH concentrations and early miscarriage through a combination of retrospective cohort study and mendelian randomization analysis.
methodsThe retrospective cohort study enrolled women who achieved intrauterine clinical pregnancies through in vitro fertilization cycles at Peking University Third Hospital between January 2019 and December 2023 (N = 19,154). These women were subsequently divided based on their anti-Müllerian hormone levels. Logistic regression and restrictive cubic spline regression models were applied to investigate the association between anti-Müllerian hormone levels and early miscarriage. Additionally, a two-step Mendelian randomization approach was utilized to investigate the causal relationship between anti-Müllerian hormone levels and miscarriage. Exposure traits were extracted from a meta-GWAS dataset (N = 9,968), while outcome traits were obtained from three separate GWAS datasets (N = 135,962, N = 360,044, and N = 150,215, respectively).
resultsIn the in vitro fertilization (IVF) cohort, there were 2,780 women with AMH<1.1ng/ml, 6,666 women with 1.1 < AMH ≤ 2.6 ng/ml, and 9,708 women with AMH ≥ 2.6ng/ml. Compared to women with AMH ≥ 2.6ng/ml, women with AMH < 1.1 ng/mL (17.7% vs. 10.9% reference; aOR = 1.26 [1.11–1.44], p < 0.001) and women with AMH 1.1–2.6 ng/mL (13.8% vs. 10.9%; aOR = 1.13 [1.02–1.25], p = 0.018) exhibited significantly higher rates of early miscarriage. The aOR of early miscarriage showed a decreasing trend as AMH levels increased in restrictive cubic spline (p < 0.001). MR analysis did not detect a causal relationship between AMH levels and spontaneous miscarriage or recurrent miscarriage.
conclusionsWomen with low AMH levels who conceive naturally do not need to worry excessively about early miscarriage. However, in the IVF population, low AMH levels warrant caution regarding the risk of early miscarriage. Future studies are necessary to confirm the causal relationship between AMH and early miscarriage in IVF cycles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.